A Phase 4 interventional study of Tramadol hydrochloride and Acetaminophen in Pain and Fibromyalgia, sponsored by Johnson & Johnson Taiwan Ltd. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-03.
Sponsored by Johnson & Johnson Taiwan Ltd (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing tramadol in Pain — 1 open to participants now, 1 under way, none of them phase 3. Tramadol · Pain.
Among the 37 studies testing tramadol in Pain, this one is the 25th largest by enrollment, is one of 6 that started in 2008, is one of 12 in phase 4, and was the 13th registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →1 of the 37 studies testing tramadol in Pain is open now, in 1 country. Recruiting first, the newest first:
Dow University of Health Sciences · Sites in Pakistan
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
Tramadol: first FDA approval 1995 (ULTRAM). What it is approved for, and how studies give it, is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 108 across the 37 interventional studies. Of the 27 that completed or were terminated, 7 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 37 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Taiwan Ltd, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Taiwan Ltd is the lead sponsor of 23 studies on the registry; none are open to participants now.
104 studies in Pain by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 99 finished, 32 (32%) have results posted.
Among the 104 studies in Pain by Johnson & Johnson, this one is the 57th largest by enrollment of the 88 interventional ones that give a count, is one of 12 that started in 2008, is one of 22 in phase 4, and was the 44th registered.
Johnson & Johnson’s Pain studies by the year they started, since 1986.
None of the studies under way reaches primary completion within a year.
Among the 37 studies testing tramadol in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 104 in Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the analgesic effect of combination of tramadol hydrochloride and acetaminophen in participants for treatment of fibromyalgia pain (chronic widespread pain and presence of tender points).
This is an open-label (all people know the identity of the intervention) and multi-center (conducted in more than one center) study of combination of tramadol hydrochloride and acetaminophen in treatment of participants with pain of fibromyalgia. The duration of this study will be 56 days per participant. The study consists of 2 parts: Screening (that is, 3 weeks before study commences on Day 1) and Treatment (that is, up to Day 56). All the eligible participants will receive oral tablet for combination of tramadol hydrochloride and acetaminophen. Rescue medication (a medication intended to relieve symptoms immediately) of tylenol (500 milligram, up to 6 oral tablets daily) will be permitted throughout the study duration. Efficacy of the participants will primarily be evaluated by Pain Visual Analog Scale. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tramadol hydrochloride/acetaminophen oral tablet will be administered as 37.5 /325 milligram respectively once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
Drug: Tramadol hydrochloride · Drug: Acetaminophen
Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
Pain Visual Analog Scale Score at Day 14
Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".
Time frame: Day 14
Pain Visual Analog Scale Score at Day 28
Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".
Time frame: Day 28
Pain Visual Analog Scale Score at Day 56
Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".
Time frame: Day 56
Number of Participants With Categorical Scores on Pain Relief Rating Scale
Pain Relief Rating Scale was used to measure the amount of pain relief experienced (on average) relative to the no-medication Screening or wash-out phase using a 6-point Likert scale ranging from (-) 1 to 4 and rated as (-) 1=worse, 0=None, 1=Slight, 2=moderate,3=a lot and 4=complete.
Time frame: Day 14, 28 and 56
Tender-Point Evaluation/ Myalgic Score
Eighteen tender-point sites were evaluated by digital palpation for pain by the same Investigator at each site. The Investigator rated the participant's response to digital palpation on a scale from 0 (no pain \[participant did not have a tender point\]) to 3 (participant withdrawn or flinched). Total myalgic score was the sum of tender-point pain ratings.The total tender-Point score ranges from 0 to 18, and the total myalgic score ranges from 0 to 54. Higher score indicates worsening.
Time frame: Baseline and Day 56
Sleep Questionnaire: Number of Hours to Fall Asleep and Participant Slept
The patient assessment sleep questionnaire consisted of 12-Questions (Q) to evaluate the participant's sleep habits out of which Q1 was "How long did it usually take for participant to fall asleep during the past 4 weeks" and Q2 was "On the average, how many hours did participant sleep each night during the past 4 weeks".
Time frame: Baseline and Day 56
Participant Assessment Sleep Questionnaire Score
Sleep questionnaire consisted of 12-Questions (Q), Q3-Q12 were related to "How often during past 4 weeks did participant felt" and are as: Q3: sleep not quiet, Q4: get enough sleep to feel rested upon waking in morning, Q5: awaken short of breath or with headache, Q6: feel drowsy or sleepy, Q7: have trouble falling asleep, Q8: awaken during sleep time and have trouble falling asleep again, Q9: trouble staying awake during day, Q10: snore, Q11: take naps during day, Q12: get amount of sleep needed. Score ranged from 1= all the time to 6 = none of the time, higher score indicates improvement.
Time frame: Baseline and Day 56
Total Fibromyalgia Impact Questionnaire (FIQ) Score
The FIQ was 19-item questionnaire which measured participant status, progress and outcomes. First 10 items made up of a physical functioning scale, ranging from 0 (always) to 3 (never). Items 11 and 12 asked participants to mark the number of days they felt well (0-7 days) and missed work (0-5 days). Items 13-19 were measured using 10 centimeter (cm) visual analog scale, score ranging from 0 cm (no) to 10 cm (very). Total FIQ score ranged from 0 -100 which was calculated as sum of final scores for item 1-10, 11 and 12, and individual score for item 13-19, and higher score indicates worsening.
Time frame: Baseline and Day 56
Number of Participants With Physician Global Assessment
The treating physician rated the participant's condition on Day 1 before the start of treatment and each return visit. The assessment included how the drug controlled the pain (Question 1 \[Q1\]), adverse event (Question 2 \[Q2\]), and overall evaluation (Question 3 \[Q3\]), and participant's condition was indicated as very good, good, moderate, poor and very poor.
Time frame: Day 14, 28 and 56
Number of Participants With Subject's Global Assessment
Participants indicated their condition on Day 1 before the start of treatment and each return visit. The assessment included how the drug controlled the pain (Question 1 \[Q1\]), adverse event (Question 2 \[Q2\]), and overall evaluation (Question 3 \[Q3\]), and participants indicated their condition as very good, good, moderate, poor and very poor.
Time frame: Day 14, 28 and 56
| Milestone | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Started | 80 |
| Completed | 40 |
| Not completed | 40 |
| Withdrew: Adverse event | 16 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Protocol violation | 8 |
| Withdrew: Participant took prohibited medication | 1 |
| Withdrew: Receive other anti-neoplastic treatment | 1 |
| Withdrew: Insufficient therapy | 1 |
Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".
| Millimeter (mm) | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Pain Visual Analog Scale Score at Day 14 | 53.0 ± 20.12 |
Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".
| Millimeter (mm) | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Pain Visual Analog Scale Score at Day 28 | 49.6 ± 20.95 |
Pain visual analog scale was used to assess the amount of pain recently experienced (within the last 48 hours) by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".
| Millimeter (mm) | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Pain Visual Analog Scale Score at Day 56 | 44.9 ± 20.95 |
Pain Relief Rating Scale was used to measure the amount of pain relief experienced (on average) relative to the no-medication Screening or wash-out phase using a 6-point Likert scale ranging from (-) 1 to 4 and rated as (-) 1=worse, 0=None, 1=Slight, 2=moderate,3=a lot and 4=complete.
| Participants | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| A lot:Day 14 | 12 |
| Moderate:Day 14 | 19 |
| Slight:Day 14 | 24 |
| None:Day 14 | 4 |
| Worse:Day 14 | 2 |
| Missing:Day 14 | 19 |
| A lot:Day 28 | 17 |
| Moderate:Day 28 | 23 |
| Slight:Day 28 | 14 |
| None:Day 28 | 5 |
| Worse:Day 28 | 3 |
| Missing:Day 28 | 18 |
| A lot:Day 56 | 25 |
| Moderate:Day 56 | 13 |
| Slight:Day 56 | 18 |
| None:Day 56 | 9 |
| Worse:Day 56 | 3 |
| Missing:Day 56 | 12 |
Eighteen tender-point sites were evaluated by digital palpation for pain by the same Investigator at each site. The Investigator rated the participant's response to digital palpation on a scale from 0 (no pain \[participant did not have a tender point\]) to 3 (participant withdrawn or flinched). Total myalgic score was the sum of tender-point pain ratings.The total tender-Point score ranges from 0 to 18, and the total myalgic score ranges from 0 to 54. Higher score indicates worsening.
| Units on a scale | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Tender-Point Evaluation (right side):Baseline | 7.9 ± 1.2 |
| Myalgic Score (right side):Baseline | 13.6 ± 4.0 |
| Tender-Point Evaluation (left side):Baseline | 7.8 ± 1.2 |
| Myalgic Score (left side):Baseline | 13.1 ± 4.1 |
| Tender-Point Evaluation (right side):Day 56 | 4.9 ± 2.5 |
| Myalgic Score (right side):Day 56 | 7.0 ± 5.3 |
| Tender-Point Evaluation (left side):Day 56 | 5.1 ± 2.4 |
| Myalgic Score (left side):Day 56 | 7.2 ± 5.2 |
The patient assessment sleep questionnaire consisted of 12-Questions (Q) to evaluate the participant's sleep habits out of which Q1 was "How long did it usually take for participant to fall asleep during the past 4 weeks" and Q2 was "On the average, how many hours did participant sleep each night during the past 4 weeks".
| Hours | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Question 1: Baseline | 3.2 ± 1.3 |
| Question 2: Baseline | 5.4 ± 1.5 |
| Question 1: Day 56 | 2.2 ± 1.2 |
| Question 2: Day 56 | 6.4 ± 1.3 |
Sleep questionnaire consisted of 12-Questions (Q), Q3-Q12 were related to "How often during past 4 weeks did participant felt" and are as: Q3: sleep not quiet, Q4: get enough sleep to feel rested upon waking in morning, Q5: awaken short of breath or with headache, Q6: feel drowsy or sleepy, Q7: have trouble falling asleep, Q8: awaken during sleep time and have trouble falling asleep again, Q9: trouble staying awake during day, Q10: snore, Q11: take naps during day, Q12: get amount of sleep needed. Score ranged from 1= all the time to 6 = none of the time, higher score indicates improvement.
| Units on a scale | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Question 3: Baseline | 2.5 ± 1.3 |
| Question 4: Baseline | 4.5 ± 1.3 |
| Question 5: Baseline | 3.8 ± 1.6 |
| Question 6: Baseline | 2.9 ± 1.5 |
| Question 7: Baseline | 2.9 ± 1.6 |
| Question 8: Baseline | 2.9 ± 1.5 |
| Question 9: Baseline | 3.5 ± 1.6 |
| Question 10: Baseline | 3.4 ± 1.5 |
| Question 11: Baseline | 3.3 ± 1.7 |
| Question 12: Baseline | 4.7 ± 1.3 |
| Question 3: Day 56 | 3.8 ± 1.3 |
| Question 4: Day 56 | 3.5 ± 1.4 |
| Question 5: Day 56 | 4.9 ± 1.1 |
| Question 6: Day 56 | 4.3 ± 1.3 |
| Question 7: Day 56 | 4.2 ± 1.5 |
| Question 8: Day 56 | 4.4 ± 1.3 |
| Question 9: Day 56 | 4.4 ± 1.4 |
| Question 10: Day 56 | 4.6 ± 1.1 |
| Question 11: Day 56 | 4.2 ± 1.4 |
| Question 12: Day 56 | 3.8 ± 1.6 |
The FIQ was 19-item questionnaire which measured participant status, progress and outcomes. First 10 items made up of a physical functioning scale, ranging from 0 (always) to 3 (never). Items 11 and 12 asked participants to mark the number of days they felt well (0-7 days) and missed work (0-5 days). Items 13-19 were measured using 10 centimeter (cm) visual analog scale, score ranging from 0 cm (no) to 10 cm (very). Total FIQ score ranged from 0 -100 which was calculated as sum of final scores for item 1-10, 11 and 12, and individual score for item 13-19, and higher score indicates worsening.
| Units on a scale | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Baseline (n=73) | 6.1 ± 1.55 |
| Day 56 (n=51) | 4.0 ± 1.94 |
The treating physician rated the participant's condition on Day 1 before the start of treatment and each return visit. The assessment included how the drug controlled the pain (Question 1 \[Q1\]), adverse event (Question 2 \[Q2\]), and overall evaluation (Question 3 \[Q3\]), and participant's condition was indicated as very good, good, moderate, poor and very poor.
| Participants | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Q1: Very good (Day 14) | 2 |
| Q1: Good (Day 14) | 18 |
| Q1: Moderate (Day 14) | 30 |
| Q1: Poor (Day 14) | 10 |
| Q1: Very poor (Day 14) | 2 |
| Q1: Missing (Day 14) | 18 |
| Q2: Very good (Day 14) | 19 |
| Q2: Good (Day 14) | 23 |
| Q2: Moderate (Day 14) | 14 |
| Q2: Poor (Day 14) | 4 |
| Q2: Very poor (Day 14) | 2 |
| Q2: Missing (Day 14) | 18 |
| Q3: Very good (Day 14) | 3 |
| Q3: Good (Day 14) | 14 |
| Q3: Moderate (Day 14) | 34 |
| Q3: Poor (Day 14) | 10 |
| Q3: Very poor (Day 14) | 1 |
| Q3: Missing (Day 14) | 18 |
| Q1: Very good (Day 28) | 3 |
| Q1: Good (Day 28) | 20 |
| Q1: Moderate (Day 28) | 19 |
| Q1: Poor (Day 28) | 7 |
| Q1: Very poor (Day 28) | 0 |
| Q1: Missing (Day 28) | 31 |
| Q2: Very good (Day 28) | 14 |
| Q2: Good (Day 28) | 22 |
| Q2: Moderate (Day 28) | 11 |
| Q2: Poor (Day 28) | 2 |
| Q2: Very poor (Day 28) | 0 |
| Q2: Missing (Day 28) | 31 |
| Q3: Very good (Day 28) | 3 |
| Q3: Good (Day 28) | 23 |
| Q3: Moderate (Day 28) | 17 |
| Q3: Poor (Day 28) | 6 |
| Q3: Very poor (Day 28) | 0 |
| Q3: Missing (Day 28) | 31 |
| Q1: Very good (Day 56) | 5 |
| Q1: Good (Day 56) | 20 |
| Q1: Moderate (Day 56) | 18 |
| Q1: Poor (Day 56) | 8 |
| Q1: Very poor (Day 56) | 1 |
| Q1: Missing (Day 56) | 28 |
| Q2: Very good (Day 56) | 13 |
| Q2: Good (Day 56) | 22 |
| Q2: Moderate (Day 56) | 13 |
| Q2: Poor (Day 56) | 2 |
| Q2: Very poor (Day 56) | 2 |
| Q2: Missing (Day 56) | 28 |
| Q3: Very good (Day 56) | 4 |
| Q3: Good (Day 56) | 26 |
| Q3: Moderate (Day 56) | 15 |
| Q3: Poor (Day 56) | 6 |
| Q3: Very poor (Day 56) | 1 |
| Q3: Missing (Day 56) | 28 |
Participants indicated their condition on Day 1 before the start of treatment and each return visit. The assessment included how the drug controlled the pain (Question 1 \[Q1\]), adverse event (Question 2 \[Q2\]), and overall evaluation (Question 3 \[Q3\]), and participants indicated their condition as very good, good, moderate, poor and very poor.
| Participants | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Q1: Very good (Day 14) | 5 |
| Q1: Good (Day 14) | 8 |
| Q1: Moderate (Day 14) | 32 |
| Q1: Poor (Day 14) | 15 |
| Q1: Very poor (Day 14) | 2 |
| Q1: Missing (Day 14) | 18 |
| Q2: Very good (Day 14) | 16 |
| Q2: Good (Day 14) | 21 |
| Q2: Moderate (Day 14) | 19 |
| Q2: Poor (Day 14) | 3 |
| Q2: Very poor (Day 14) | 3 |
| Q2: Missing (Day 14) | 18 |
| Q3: Very good (Day 14) | 3 |
| Q3: Good (Day 14) | 8 |
| Q3: Moderate (Day 14) | 38 |
| Q3: Poor (Day 14) | 13 |
| Q3: Very poor (Day 14) | 0 |
| Q3: Missing (Day 14) | 18 |
| Q1: Very good (Day 28) | 3 |
| Q1: Good (Day 28) | 15 |
| Q1: Moderate (Day 28) | 21 |
| Q1: Poor (Day 28) | 7 |
| Q1: Very poor (Day 28) | 3 |
| Q1: Missing (Day 28) | 31 |
| Q2: Very good (Day 28) | 16 |
| Q2: Good (Day 28) | 16 |
| Q2: Moderate (Day 28) | 13 |
| Q2: Poor (Day 28) | 4 |
| Q2: Very poor (Day 28) | 0 |
| Q2: Missing (Day 28) | 31 |
| Q3: Very good (Day 28) | 3 |
| Q3: Good (Day 28) | 17 |
| Q3: Moderate (Day 28) | 21 |
| Q3: Poor (Day 28) | 8 |
| Q3: Very poor (Day 28) | 0 |
| Q3: Missing (Day 28) | 31 |
| Q1: Very good (Day 56) | 4 |
| Q1: Good (Day 56) | 18 |
| Q1: Moderate (Day 56) | 19 |
| Q1: Poor (Day 56) | 10 |
| Q1: Very poor (Day 56) | 1 |
| Q1: Missing (Day 56) | 28 |
| Q2: Very good (Day 56) | 14 |
| Q2: Good (Day 56) | 21 |
| Q2: Moderate (Day 56) | 9 |
| Q2: Poor (Day 56) | 4 |
| Q2: Very poor (Day 56) | 4 |
| Q2: Missing (Day 56) | 28 |
| Q3: Very good (Day 56) | 4 |
| Q3: Good (Day 56) | 16 |
| Q3: Moderate (Day 56) | 25 |
| Q3: Poor (Day 56) | 7 |
| Q3: Very poor (Day 56) | 0 |
| Q3: Missing (Day 56) | 28 |
Collected over Baseline up to Day 56. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tramadol Hydrochloride/Acetaminophen | — | 2/80 (2.5%) | 49/80 (61.3%) |
| Event | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Forearm fractureInjury, poisoning and procedural complications | 1/80 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/80 |
| Event | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| DizzinessNervous system disorders | 14/80 |
| Dry mouthGastrointestinal disorders | 12/80 |
| NauseaGastrointestinal disorders | 9/80 |
| VomitingGastrointestinal disorders | 5/80 |
| SomnolencePsychiatric disorders | 5/80 |
| ConstipationGastrointestinal disorders | 4/80 |
| VertigoNervous system disorders | 4/80 |
| PruritusSkin and subcutaneous tissue disorders | 4/80 |
| AstheniaGeneral disorders | 3/80 |
| Drug eruptionImmune system disorders | 3/80 |
| Age Continuous(Years) | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Mean | 50.4 ± 10.01 |
| Sex: Female, Male(Participants) | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Female | 74 |
| Male | 6 |
| Pain Visual Analog Scale at Baseline(Units on a scale) | Tramadol Hydrochloride/Acetaminophen |
|---|---|
| Mean | 71.3 ± 18.22 |
No study locations are listed for this record.
The record gives a start of Oct 2008, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tramadol · Acetaminophen
Johnson & Johnson Taiwan Ltd →